Sugi Predict

Sugi Predict / Compounds / SCHEMBL1888903

SCHEMBL1888903

SCHEMBL1888903

Cc1cccc(-c2ccc(-c3ccc(O)cc3CCC(=O)O)cc2CO)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FFAR1 O14842 7/20 0.51
▸ FFAR4 Q5NUL3 5/20 0.51
▸ PTGER4 P35408 5/20 0.47
▸ PTGER3 P43115 5/20 0.47
▸ PTGER1 P34995 4/20 0.47
▸ PTGER2 P43116 4/20 0.47
▸ CNR2 P34972 1/20 0.41
▸ RXRA P19793 2/20 0.41
▸ RXRB P28702 2/20 0.41
▸ RXRG P48443 2/20 0.41
▸ NR4A2 P43354 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ MME P08473 1/20 0.39
▸ CA12 O43570 1/20 0.39
▸ CA9 Q16790 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16863743 0.93 FFAR1 (0.51) FFAR1FFAR4PTGER4PTGER3PTGER1
SCHEMBL38659420 0.89 FFAR1 (0.50) FFAR1FFAR4PTGER4PTGER3PTGER1
SCHEMBL1811354 0.89 FFAR1 (0.50) FFAR1FFAR4PTGER4PTGER3PTGER1
SCHEMBL1892708 0.89 FFAR1 (0.52) FFAR1FFAR4PTGER4PTGER3PTGER1
SCHEMBL38660533 0.86 CYP4F2 (0.50) FFAR1FFAR4CNR2KDM4EMEN1
SCHEMBL1810558 0.86 CYP4F2 (0.50) FFAR1FFAR4CNR2KDM4EMEN1
SCHEMBL15948945 0.85 FFAR1 (0.48) FFAR1FFAR4PTGER4PTGER3PTGER1
SCHEMBL38660342 0.85 FFAR1 (0.48) FFAR1FFAR4PTGER4PTGER3PTGER1
SCHEMBL1802536 0.85 FFAR1 (0.48) FFAR1FFAR4PTGER4PTGER3PTGER1
SCHEMBL1886592 0.85 FFAR1 (0.53) FFAR1FFAR4PTGER4PTGER3PTGER1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160184274-A1 Methods for inhibiting mesenchymal phenotype after epithelial-to-mesenchymal transition UNIVERSITAT DE VALENCIA (ES) 2016-06-30 — — US claimed
EP-2496544-B1 GPBP INHIBITION USING Q2 PEPTIDOMIMETICS FIBROSTATIN S L (SE) 2014-08-20 — — EP claimed
US-8586776-B2 GPBP inhibition using Q2 peptidomimetics FIBROSTATIN, S.L. (ES) 2013-11-19 — — US claimed
US-20110105545-A1 GPBP inhibition using Q2 peptidomimetics FIBROSTATIN, S.L. (ES) 2011-05-05 — — US claimed
US-10544083-B2 GPBP inhibition using Q2 peptidomimetics UNIVERSITAT DE VALÈNCIA (ES) 2020-01-28 — — US disclosed
US-10544083-B2 GPBP inhibition using Q2 peptidomimetics UNIVERSITAT DE VALÈNCIA (ES) 2020-01-28 — — US disclosed
US-20180179139-A1 GPBP inhibition using Q2 peptidomimetics FIBROSTATIN, S.L. (ES) 2018-06-28 — — US disclosed
US-20180179139-A1 GPBP inhibition using Q2 peptidomimetics FIBROSTATIN, S.L. (ES) 2018-06-28 — — US disclosed
US-20160184274-A1 Methods for inhibiting mesenchymal phenotype after epithelial-to-mesenchymal transition UNIVERSITAT DE VALENCIA (ES) 2016-06-30 — — US disclosed
US-20160083327-A1 GPBP inhibition using Q2 peptidomimetics JUAN SAUS (ES) 2016-03-24 — — US disclosed
US-20160083327-A1 GPBP inhibition using Q2 peptidomimetics JUAN SAUS (ES) 2016-03-24 — — US disclosed
US-20160083327-A1 GPBP inhibition using Q2 peptidomimetics JUAN SAUS (ES) 2016-03-24 — — US disclosed
US-20140080852-A1 GPBP inhibition using Q2 peptidomimetics FIBROSTATIN, S.L. (ES) 2014-03-20 — — US disclosed
US-20140080852-A1 GPBP inhibition using Q2 peptidomimetics FIBROSTATIN, S.L. (ES) 2014-03-20 — — US disclosed
US-8586776-B2 GPBP inhibition using Q2 peptidomimetics FIBROSTATIN, S.L. (ES) 2013-11-19 — — US disclosed
US-8586776-B2 GPBP inhibition using Q2 peptidomimetics FIBROSTATIN, S.L. (ES) 2013-11-19 — — US disclosed
WO-2011054530-A1 GPBP INHIBITION USING Q2 PEPTIDOMIMETICS FIBROSTATIN, S.L. (ES) 2011-05-12 — — WO disclosed
US-20110105545-A1 GPBP inhibition using Q2 peptidomimetics FIBROSTATIN, S.L. (ES) 2011-05-05 — — US disclosed
US-20110105545-A1 GPBP inhibition using Q2 peptidomimetics FIBROSTATIN, S.L. (ES) 2011-05-05 — — US disclosed
US-20110105545-A1 GPBP inhibition using Q2 peptidomimetics FIBROSTATIN, S.L. (ES) 2011-05-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10544083-B2 GPBP inhibition using Q2 peptidomimetics HSP90B1, ERP44, HSPA5 FFAR1 2951/4885FFAR4 2889/4885PTGER4 1660/4885
US-20140080852-A1 GPBP inhibition using Q2 peptidomimetics HSP90B1, ERP44, HSPA5 FFAR1 2951/4885FFAR4 2889/4885PTGER4 1660/4885
US-20110105545-A1 GPBP inhibition using Q2 peptidomimetics HSP90B1, ERP44, HSPA5 FFAR1 2951/4885FFAR4 2889/4885PTGER4 1660/4885
US-20160184274-A1 Methods for inhibiting mesenchymal phenotype after epithelial-to-mesenchymal transition VIM, EPCAM, CDH1 FFAR1 4443/4885FFAR4 4492/4885PTGER4 3062/4885
US-20180179139-A1 GPBP inhibition using Q2 peptidomimetics HSP90B1, ERP44, HSPA5 FFAR1 2951/4885FFAR4 2889/4885PTGER4 1660/4885
US-20160083327-A1 GPBP inhibition using Q2 peptidomimetics HSP90B1, ERP44, HSPA5 FFAR1 2951/4885FFAR4 2889/4885PTGER4 1660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.